Abstract
Pharmaceutical research is associated with high costs, both in terms of time and money. In the last year, drugs with a value of over $20 billion have come off patent, meaning many pharma giants face a crisis in their late-stage product pipeline. This, in addition to the high risks involved in getting a drug to market, encourages maximal exploitation of drugs already proven safe.
| Original language | English |
|---|---|
| Pages (from-to) | 100-103 |
| Number of pages | 4 |
| Journal | European Pharmaceutical Contractor |
| Publication status | Published - Sept 2007 |
ASJC Scopus subject areas
- Pharmaceutical Science